Urteste

Urteste Debt/Market Cap

The Debt to Market Capitalization Ratio of Urteste (URT.WA) as of Oct 29, 2026 is 3.82 %. In the previous year, Debt to Market Capitalization Ratio was 0.53 % — a change of 616.87% (higher).

Debt/Market Cap

3.82 %

YoY

616.87%

Last updated:

Debt to Market Capitalization Ratio of Urteste is 2025 3.82 % . Debt to Market Capitalization Ratio of Urteste was 2024 0.53 % . It decreases by 616.87% higher compared to the previous year.

The Urteste Debt/Market Cap history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/Market Cap
Date
Debt/Market Cap
Jan 1, 2021
0.91 PLN
Jan 1, 2022
0.77 PLN
Jan 1, 2023
0.81 PLN
Jan 1, 2024
0.53 PLN
Jan 1, 2025
3.82 PLN
The Urteste Debt/Market Cap history
YEARDebt/Market CapYoY
3.82 %+616.87%
0.53 %-33.81%
0.81 %+5.03%
0.77 %-15.92%
0.91 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Urteste Stock analysis

What does Urteste do? Urteste SA develops technology for early cancer detection through urine-based enzyme activity measurement, offering diagnostic tests for multiple cancers including pancreatic, prostate, colorectal, lung, kidney, liver, biliary tract, stomach, esophageal, ovarian, endometrial, breast, leukemia, lymphoma, and glioma. The company operates in the medical devices sector for in vitro diagnostics, targeting healthcare providers and diagnostic laboratories that require early-stage cancer screening solutions. Its products enable non-invasive testing for common cancers, providing a competitive advantage in early detection markets. Urteste SA's business model focuses on selling diagnostic kits and test services directly to hospitals and specialized medical facilities. The firm's technology differentiates itself by analyzing enzyme activity in urine samples, allowing for the detection of various cancers without invasive procedures. This approach appeals to healthcare institutions seeking efficient, cost-effective screening methods for high-risk patient populations. Urteste SA's product portfolio includes specific tests for each listed cancer type, catering to the growing demand for early cancer diagnostics in clinical settings. The company's revenue streams derive from the sale of diagnostic kits and associated testing services to medical facilities that implement these tests in their screening protocols. Urteste SA's target market consists of hospitals, diagnostic laboratories, and specialized medical centers that prioritize early cancer detection as part of their patient care strategies. These institutions purchase the company's diagnostic tests to enhance their screening capabilities and improve patient outcomes through timely interventions. The firm's offerings address the specific needs of healthcare providers looking for reliable, non-invasive methods to detect multiple cancer types simultaneously. By focusing on urinary enzyme analysis, Urteste SA positions itself as a key provider of innovative diagnostic solutions in the cancer screening market. Urteste is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Urteste stock

Debt to Market Capitalization Ratio of Urteste is 3.82 % in 2025.

Debt to Market Capitalization Ratio of Urteste changed from 0.53 % to 3.82 %, representing a 616.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt to Market Capitalization Ratio Urteste since 2006 – with annual values, charts, and detailed analysis.

Debt/Market Cap compares total debt to the market value of equity. It provides a market-based view of financial leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt to Market Capitalization Ratio's Urteste with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Urteste

All Key Metrics — Urteste